Hana Hitching’s “human ash” pills turn binge diet culture into ghost horror

Saccharine, the supernatural horror with a rumbling stomach at its center, gives body-image anxiety a literal delivery system. Hana Hitching, a first-year medical student played by Midori Francis, is shown ping-ponging between binge eating and regimented workout routines, then fixating on how she could drop down to her ideal weight. The “quick fix” arrives through diet-books-in-the-drawer territory, but the film makes the bargain darkly explicit: Hana begins taking an illicit supplement guaranteed to make the weight “melt off.” The secret ingredient? Human ash.

That is where Saccharine turns the familiar script of extreme diet culture into something you cannot unsee. Soon Hana begins to be stalked by a ghostly presence, the woman whose cremated last remains Hana has been consuming. The movie also threads in a cruel motto that it treats as both logic and poison: nothing tastes as good as skinny feels. A formerly overweight friend, who previously took the same pills, experiences the same ensuing anxiety and audio hallucinations, and tells Hana, in effect, that it was “worth it.” The horror is not just the supernatural haunting, it is the emotional sales pitch that survives long after the cost.

For executives, here is the market-reality angle: Hollywood keeps revisiting body-image anxieties because they are commercially reliable. The Guardian piece frames Saccharine as part of a stack of recent releases, including melodramatic comedy Maddie’s Secret, that serve disordered eating fears as entertainment. That is important because it signals demand, not necessarily endorsement. Still, when media repeats themes of illicit weight-loss methods, the “edgy” storytelling can blur into normalization for the exact audience it intends to warn.

And Saccharine does not handle that blur politely. Early visuals reinforce long-running issues, including a brief shot of diet books stashed away in Hana’s drawer. This matters because disordered eating narratives often work best when they look like everyday life, not like sudden catastrophe. Hana’s routine of trying to engineer her body through cycles of overeating and intense exercise is framed as ongoing, not episodic, which can make the underlying incentive system feel familiar rather than fictional. Then the film escalates it with the supplement, which is sold as a guarantee and positioned as irresistible once “melt off” enters the conversation.

The second-order implication for anyone funding, distributing, or licensing content in this space is reputational risk with a compliance-shaped edge. You do not have to be a healthcare company to get dragged into the public debate about eating disorders, harmful diet culture, or the promotion of unsafe practices. When a plot centers on an illicit supplement and explicitly depicts anxiety and audio hallucinations following use, audiences and advocacy groups can reasonably ask whether the story glamorizes or trivializes harm. Even if the film is clearly using horror conventions to critique the cycle, the practical question for brands and platforms is how they will be interpreted in the feed, in reviews, and in discussions.

Regulatory background here is less about a regulator deciding whether a movie is “true,” and more about how a larger ecosystem treats health-adjacent content. In many jurisdictions, misleading health claims in advertising are regulated with varying degrees of strictness, while entertainment content is often handled through classification and consumer protection norms rather than clinical oversight. But when stories revolve around weight-loss “guarantees,” illicit pills, and a mechanism marketed as working, the visual language can still echo marketing tropes that regulators have reason to scrutinize elsewhere. That is the uncomfortable overlap: not that film regulators are issuing recalls, but that the same trust-adjacent narratives can trigger scrutiny when they resemble real-world scams.

There is also the board-level issue of signal. Maddie’s Secret, described in the Guardian piece as a melodramatic comedy, joins Saccharine in the broader pattern of body-image anxiety being served in different genres. When a slate includes both melodrama and supernatural horror built around disordered eating fears, it tells the market that these stories are not just tolerated, they are expected. That can attract investment, but it can also encourage copycat pitching that pushes too far toward shock value and too little toward responsible framing. The lesson is not “stop making these films.” The lesson is to understand what audiences are already sensitized to, and whether your distribution, marketing, and public messaging anticipate the ethical questions, not just the box office conversation.

In Saccharine, the cruel motto is not a one-liner for flavor. It is the engine of the plot, and it is delivered through a scene that encapsulates why extreme diet culture is so hard to escape: a person who took the same pills and suffered the same anxiety still frames it as “worth it.” That is the haunting part. Executives in media, brand partnerships, and platform policy teams should treat this as a stress test for how content lands after release, in secondary commentary, and in the algorithmic life of clips. The strategic stake is simple: if your ecosystem profits from attention around disordered eating themes, you also inherit the responsibility of how harm narratives propagate. Saccharine makes that propagation look like a ghost. In the real world, the “haunting” is reputational, regulatory-adjacent, and it arrives fast.